Latest News and Press Releases

Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS...

Full Year Net Sales of $161.7 million including Proprietary Brand Sales of $44.0 million Full Year Proprietary Brand Penetration Increased to 32.8% up from 24.2% in the prior year Full Year GAAP...

Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general...

– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque...

Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with...

NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 Advancing...

Paris, le 19 mars 2026 MISE À DISPOSITION DU DOCUMENT D’ENREGISTREMENT UNIVERSEL 2025INCLUANT LE RAPPORT FINANCIER ANNUEL Le Document d’enregistrement universel d’Hermès International relatif à...

Paris, 19 March 2026 AVAILABILITY OF THE 2025 UNIVERSAL REGISTRATION DOCUMENTINCLUDING THE ANNUAL FINANCIAL REPORT Hermès International filed its 2025 Universal Registration Document with the...

COURTOIS SASociété anonyme au capital de 1.673.940 EurosSiège social : 3, rue Mage BP 4853131685 TOULOUSE CEDEX 6540 802 105 RCS TOULOUSETel : 05.62.26.73.22Contact...

Fangzhou reported its 2025 annual results, posting strong revenue growth and achieving full-year profitability.